LP-284 Updated Sep 13
Watch for the next Phase 1 data update from LP-284's ongoing trial (NCT06132503), likely at a hematology/oncology medical conference in H1 2027. The stock is highly speculative at ~$1.71 with a ~923% implied analyst upside, but Phase 1 assets carry high failure risk. Monitor cash runway, Lantern's May 2026 offering raised capital but also diluted existing holders. Any meaningful partnership or accelerated development pathway would be a major positive catalyst.
- Early efficacy signal is compelling: a complete metabolic response in a DLBCL patient who had exhausted CAR-T and bispecific antibody therapies, a very difficult-to-treat population (source: Lantern Pharma press release, Oct 2025 LL&M Congress)
- Three FDA Orphan Drug Designations (mantle cell lymphoma, high-grade B-cell lymphoma, soft tissue sarcomas) provide market exclusivity potential and development incentives (source: FDA catalysts data, SEC filings)
- Analyst consensus is strongly bullish: 7 of 8 analysts rate Buy/Strong Buy with a mean price target of $17.50, implying ~923% upside from $1.71
- Phase 1 only, the vast majority of Phase 1 oncology drugs never achieve FDA approval; early single-patient complete responses often fail to replicate in larger cohorts
- Micro-cap risk: LTRN trades near $1.71 with a ~$22M market cap; the May 2026 securities offering that raised capital also diluted existing shareholders (insider warrants at $2.27 strike)
- Mixed institutional signals: BlackRock trimmed -50.6% and Dimensional Fund Advisors trimmed -56.1% of their LTRN positions in Q2 2026